Devonian Health Group (CVE:GSD) Shares Up 0.8% – Should You Buy?

Devonian Health Group Inc. (CVE:GSD) shot up 0.8% during mid-day trading on Thursday . The stock traded as high as C$12.00 and last traded at C$12.00. 1,191 shares changed hands during trading, a decline of 11% from the average session volume of 1,337 shares. The stock had previously closed at C$11.90.

Devonian Health Group Price Performance

The company has a market capitalization of C$33.19 million, a P/E ratio of -4.35 and a beta of 1.14. The stock’s fifty day simple moving average is C$11.29 and its 200-day simple moving average is C$10.81. The company has a debt-to-equity ratio of 16.36, a current ratio of 1.07 and a quick ratio of 7.82.

Devonian Health Group Company Profile

Devonian Health Group Inc engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics. In addition, the company acquires drug and health product licenses; and distributes pharmaceutical products.